GlassScriptPhysician profile
Ayman M Jabr
NPI 1669582417
$19,641.79
in general payments reported to CMS, 2019-2025
41 companies · $2,110 in 2025
The $2,110 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,091 · 2020: $2,464 · 2021: $2,481 · 2022: $2,551 · 2023: $3,152 · 2024: $2,794 · 2025: $2,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,036 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,035.69 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,128.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $1,793.94 | 2019-2025 | |
| Lilly USA, LLC | $1,623.29 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $1,517.28 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $1,281.53 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $1,132.24 | 2021-2025 | |
| Amgen INC. | $979.27 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Novartis Pharmaceuticals Corporation | $948.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $809.93 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $771.98 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $728.13 | 2019-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $614.75 | 2019-2024 | |
| Mylan Specialty L.P. | $601.49 | 2022-2024 | Yupelri |
| Abbvie INC. | $476.19 | 2021-2025 | |
| Allergan, INC. | $417.37 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Jabr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.